Published in Vaccine Weekly, July 30th, 2003
Punnee Pitisuttithum and colleagues at Mahidol University in Bangkok and other institutions in Thailand and the United States assessed the "safety and immunogenicity of two recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein (gp) 120 vaccines derived from SF2 (subtype B) and CM235 (CRF01_AE, Thai E)".
Vaccine recipients demonstrated robust cellular and humoral activity against HIV gp120, Pitisuttithum and coauthors said.
In their study, a group of 370 Thai adults were immunized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly